Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 35 Note 15: Issued capital Number $’000s Opening balance at 1 July 2019: 104,034,437 47,028 Movement in ordinary share capital Share placement 35,714,286 35,000 Share Purchase Plan 2,551,023 2,500 Repayment of loans over employee share plan shares - 1,234 Exercise of employee share options 311,250 143 Less: Share issue costs - (1,892) Closing balance at 30 June 2020 142,610,996 84,013 Movement in ordinary share capital Exercise of employee share options 296,250 163 Less: Share issue costs - (12) Closing balance as at 30 June 2021 142,907,246 84,164 All fully paid ordinary shares and founder shares have equal voting rights, of one vote per share, and subject to the prior rights of preference shares, have equal rights to receive dividends in proportion to the number of ordinary shares held. Note 16: Reserves Share based payments reserve Consolidated 2021 2020 $’000s $’000s Balance 1 July 1,985 1,413 Transferred to accumulated losses upon forfeiture (235) (59) Share-based payment expenses 1,719 631 Balance 30 June 3,469 1,985 The share-based payments reserve is used to recognise the fair value of equity benefits provided to employees and Directors as part of their compensation. Foreign currency translation reserve Consolidated 2021 2020 $’000s $’000s Balance 1 July (155) (44) Arising from translation of foreign subsidiaries 20 (111) Balance 30 June (135) (155) The foreign currency translation reserve is used to recognise the exchange difference on the translation of the US and UK subsidiaries into AUD. Financial Report